Concepedia

Publication | Open Access

Phase 1 dose‐escalation trial evaluating the combination of the selective MET (mesenchymal‐epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib

DOIFull Paper Access

76

Citations

30

References

2012

Year

Jonathan W. Goldman, Isett Laux, Ronald E. Savage, Dora Ferrari, Edward G. Garmey, R. Just, Lee S. Rosen
Cancer

Abstract

Tivantinib plus erlotinib was well tolerated with encouraging clinical activity, especially in patients with nonsmall cell lung cancer.

References

YearCitations

Page 1